Replies to post #166776 on Biotech Values

[DewDiligence]

Re: ENTA valuation model

Is that your target today? If not what is your time frame. I didn't notice any DCF analysis in your model.

Thanks for asking. The calculations in #msg-92234861 refer to ENTA’s target price following ABBV’s HCV product launch in 1H15, assuming no delay in FDA and EU approvals (and also no delay for GILD’s all-oral approvals in genotype-1 patients). Readers can use whatever discount rate and risk adjustment they want to derive an NPV figure.